My Profile   |   Print Page   |   Contact Us   |   Sign In   |   Register
ASAP Blog
Blog Home All Blogs
Welcome to ASAP Blog, the best place to stay current regarding upcoming events, member companies, the latest trends, and leaders in the industry. Blogs are posted at least once a week; members may subscribe to receive notifications when new blogs are posted by clicking the "Subscribe" link above.

 

Search all posts for:   

 

Top tags: alliance management  alliances  collaboration  partnering  alliance  partner  partners  partnerships  alliance managers  ecosystem  alliance manager  The Rhythm of Business  partnership  Jan Twombly  Vantage Partners  biopharma  governance  Eli Lilly and Company  strategy  Strategic Alliance Magazine  collaborations  IBM  cloud  IoT  strategic alliances  ASAP BioPharma Conference  healthcare  innovation  Christine Carberry  Cisco 

Pharma and Tech’s Excellent Adventure: Making the Journey to Digital Health

Posted By Michael J. Burke, Monday, October 5, 2020

The road to digital health has been paved with good intentions: it’s about helping people take charge of their own health and wellness, after all. But it’s been a rocky road as well, and for pharma and tech companies taking the trip together, it’s been at times a bumpy ride filled with pitfalls, detours, and even mutual incomprehension. Nonetheless, there’s great opportunity for those hardy souls brave enough and savvy enough—and patient enough—to overcome the obstacles and stay the course.

This was among the insights gleaned from a fascinating panel moderated by Brooke Paige, CSAP, currently ASAP’s board chair and formerly vice president of alliance management at Pear Therapeutics, where she was deeply involved in digital health initiatives, called “Preparing for the Journey in Digital Health: When Healthcare’s Path Forward Leads Through Silicon Valley,” held on the final day of the recently completed ASAP BioPharma Conference.

So What Is It?

First of all, what is digital health, anyway? According to panelist Christopher Lento, head of healthcare strategic partnerships at Noom, “there are a lot of definitions floating around,” but he defined digital health as “any technology that allows patients to take ownership or engagement of their own care.”

Lento noted that nearly a thousand companies are currently working on digital therapeutics, and another panelist, Knut Sturmhoefel, CA-AM, PhD, global head of alliance management at Novartis International AG and a new ASAP board member, added that there are now many digital/biopharma partnerships. “It’s a broad spectrum of collaborations we’re starting to see,” he said, while cautioning that “we’re all learning at the moment. There’s no one model to manage these.”

That could make digital health a fertile field for the application of alliance management, of course. Lento said that in his experience, digital health often involves smaller teams, companies, and startups, especially on the tech side, and thus cofounders may get involved in managing these relationships. But he thinks there are many instances where it would be great to see a trained alliance manager stepping in and “grabbing control of the relationship” in a helpful way.

“I hope there’s an alliance manager who steps up,” he said. “It looks normal, but we’re trying to get to know each other. If you can get along, you could be on the path to great things. If there’s friction early on, you should probably take a pause.”

Seeing the Elephant

Another panelist, Davina Pallone, vice president for product at Fruit Street, addressed the big elephant in the room: the vast differences in outlook, timelines, and methods between tech or digital companies and those in the biopharma sphere. She noted that the tech side tends to operate with a “fail-fast mentality” derived from agile software development, marked by rapid code release, quick product launch, and ongoing, nearly continuous iteration and improvement of the product.

“It is a mismatch for the life cycle on the pharma side,” she acknowledged. “You don’t ‘fail fast’ with human subjects.” Or, as Lento described the pharma reaction: “What?! You’re changing the product on a daily basis?” Sturmhoefel also added that “quick changes are not what you can introduce in a product” when regulatory agencies such as the FDA are involved.

Thus, as Pallone put it, a tight collaboration and cooperation between the product and regulatory teams is absolutely necessary for success, ideally leading to a “happy medium” where you fail fast, but don’t put patients at risk.

“Fresh Tracks in the Snow”: The Promise of Digital in the Age of COVID-19

Still, because there’s so much opportunity in the area of digital health, “we’re watching so many great things happen,” according to Lento. Companies are engaging in partnerships of all kinds that are patient focused and centered on improving both access to and quality of healthcare. These partnerships are definitely breaking new ground in many cases, or as he said, “making fresh tracks in the snow.”

Pallone noted that telemedicine, one of the subsets of digital health, has certainly been “given legs” by the demands of COVID-19. “Everyone is really rethinking how often brick and mortar needs to be involved in the delivery of care.”

Lento even opined that the coronavirus has accelerated and even created more space for digital health initiatives. “As horrible as the global pandemic has been, there is some light here,” he said, pointing to cognitive behavioral therapy programs and coaching that can be delivered direct to consumers via digital therapeutics, perhaps helping to ease isolation and stress suffered by “those in need.”

“There’s a tremendous opportunity for those looking to make that jump” into the field—especially if they can help bridge the divides between digital and pharma, he said.

Pallone noted “the promise of digital: you can keep making it better and better. It’s not always well understood on the pharma side.” Still, there are going to be bumps in the road, and even failures, she said.

“What’s causing the failure is massive amounts of learning,” she explained. “You have to get out there and you’re going to take some knocks.”

The solution? More collaboration, and more buy-in from providers and patients. Better and better products and solutions. And while we’re at it, more peace, love, and understanding between “the pharma side” and “the tech side,” and more willingness to fail fast and keep iterating while still protecting patients’ health.

If you registered for the 2020 ASAP BioPharma Conference, don’t forget that you can still access both livestream and on-demand content from the conference until Nov. 13. And keep checking this space for more posts on some of the great sessions like this one featured as well.

Tags:  alliance management  Brooke Paige  Christopher Lento  collaborations  Davina Pallone  Digital Health  digital therapeutics  engagement  Fruit Street  healthcare  Knut Sturmhoefel  life cycle  Noom  Novartis digital/biopharma partnerships  patients  pharma  regulatory  strategic partnerships  tech 

Share |
PermalinkComments (0)
 

ASAP Welcomes New Board Members

Posted By Michael J. Burke, Friday, August 21, 2020

ASAP is extremely pleased to announce the appointment of four new members to its board of directors in recent months.

The new ASAP board members are: Kriti Kapoor, former head of social media and online communities, customer service and support at Microsoft and currently the founder of Automation Ready Inc.; Knut Sturmhoefel, CA-AM, vice president and global head of alliance management at Novartis; and Sally Wang, group vice president, global alliances and partnerships at International SOS. In addition, within the past six months Lucinda (Cindy) Warren, vice president of Janssen business development, neuroscience, for Janssen Business Development/Johnson & Johnson Innovation, has also joined the ASAP board.

“We’re very excited to have Kriti, Knut, and Sally join Cindy and our excellent group of board members as our newest additions to ASAP’s board of directors,” said Michael Leonetti, CSAP, president and CEO of ASAP. “They truly enhance and diversify the depth and breadth of experience we have on our outstanding board of directors, and they bring a wealth of knowledge and expertise to the association which I know will help us immeasurably as we move forward into the future, with all the challenges of these times. I expect they can help us by serving on some of our board’s standing committees, such as membership, finance, and editorial, and through their financial and operational oversight, including approval of the association’s annual budget. And most of all, they’ll come to the table with fresh thinking and new ideas, and we’ll reap the benefits of their experience and knowledge as they contribute to the ongoing governance, growth, and success of ASAP.”

Kriti Kapoor’s long tech career includes stints at Microsoft, HP, and the hypergrowth automation startup UiPath. In her technology marketing and customer care leadership roles, she’s been a builder of online communities and diverse, high-performing teams, not only in the US but in Asia Pacific, Japan, and EMEA. She has a proven track record in her career of successfully executing across multiple functions covering customer service, field and regional marketing, product management, and technology sales, driven by data analytics and customer insights and partnerships. Kriti holds an MBA from the London Business School, and a BSc in computer science from the National University of Singapore. She serves as an advisory board member of the CMO Council Asia Pacific, and was an executive sponsor of HP’s Americas Women’s Leadership Council.

Knut Sturmhoefel is vice president and global head of alliance management at Novartis. He has worked in business development at Novartis since 2005, with broad experience in partnering and deal transactions including more than seven years in alliance management. Knut has a background in research and drug development across different therapeutic areas, including immuno-oncology and ophthalmology. He previously worked at the German Cancer Research Center, as Fogarty Fellow at the US National Institutes of Health, and at two biotech companies in the Boston area (Genetics Institute and Lexigen) before joining Novartis in 2002 as a project manager. He earned his PhD in immunology from Ruprecht-Karls-Universität Heidelberg and holds a master’s certificate in project management from George Washington University.

Sally Wang’s career spans over 20 years in operations, business development, product development, alliance management, and strategy. She currently manages global strategic partnerships for International SOS as group vice president of global alliances and partnerships. Sally works closely with the International SOS senior leadership team and business units globally to identify, develop, and operate critical business relationships to help International SOS grow its capability and global footprint. She and her team manage a portfolio of global partners that includes technology, security, mental health, travel, and professional service companies. She has built a strong partnership division at International SOS, which has been both a winner and a finalist in ASAP’s Alliance Excellence Awards. Sally also advises nonprofit organizations on strategy and partnerships management, and currently serves as vice chair for St. Christopher’s Foundation for Children, an organization in Philadelphia that improves children’s health and dental care through community outreach and education.

Lucinda (Cindy) Warren has been a featured speaker at past ASAP events, including most recently the 2019 ASAP BioPharma Conference and 2019 ASAP European Summit. She heads the Neuroscience Business Development Team at Janssen, which includes scientific finding, licensing transactions, mergers, acquisition, out-licensing, divestitures, and alliance management. With over 24 years of broad industry experience, Cindy began her pharma career in Canada. In 1999, she joined the Johnson & Johnson Family of Companies and has held various US and global roles of increasing responsibility, including sales, marketing, new product development, alliance management, and business development leadership. Just prior to joining the Janssen Business Development Leadership Team, Cindy led the Immunology Business Unit in Australia, returning to the US in 2014 as vice president of alliance management, Janssen, responsible for leading the total pharmaceutical portfolio of collaborations. She received her bachelor of science degree from the University of Alberta, Canada.

As ASAP welcomes these four new board members, we also say goodbye to some longtime ASAP stalwarts who have recently stepped down from the board: Russ Buchanan, CSAP, former vice president of global channel strategy alliances and operations at Xerox and chairman emeritus of ASAP’s board; Donna Peek, CSAP, former vice president of global alliances at Genpact, who steps down as board secretary; and Steve Twait, CSAP, vice president of alliance and integration management at AstraZeneca, who steps aside as board treasurer. We’re very grateful for their service on the board and for all their contributions to ASAP. We wish Russ and Donna all the best in their retirement, and we’re thankful that we’ll continue to have the support and leadership behind the scenes from Steve.

Tags:  ASAP Board of Directors  AstraZeneca  Automation Ready Inc.  Donna Peek  Genpact  International SOS  Janssen Business Development/Johnson & Johnson Inn  Knut Sturmhoefel  Kriti Kapoor  Lucinda (Cindy) Warren  Novartis  Russ Buchanan  Sally Wang  Steve Twait  Xerox 

Share |
PermalinkComments (0)
 
For more information email us at info@strategic-alliances.org or call +1-781-562-1630